How Bionaut Labs aims to tackle brain tumors with microrobots

March 15, 2021 By Brian Buntz

Bionaut Labs The roboticist Michael Shpigelmacher was one of the founders of PrimeSense, a robotic 3-D vision technology company Apple acquired in 2013.

PrimeSense created technology empowering the Microsoft Xbox Kinect and the iPhone’s Face ID feature, allowing users to use facial recognition to unlock their phones.

Now Shpigelmacher has set his sights on drug-delivery with Bionaut Labs, a startup aiming to use tiny robots for precision drug dosing. Bionaut recently won $20 million in venture capital funding.

Get the full story from our sister site, Drug Delivery Business.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at [email protected].